GPR35 and metabolic dysfunction-associated steatotic liver disease: As GPR35 agonism is increasingly investigated to treat inflammatory bowel disease, non-alcoholic fatty liver disease, and cardiac ischemia8,39,43 it is likely that improved highly potent small molecules will be designed to target the receptor and these compounds could have efficacy in treating osteoporosis.